UY28474A1 - Formulación en polvo que contiene el antagonista de cgrp 1-(n2-(3,5-dibromo-n-((4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-piperidinil)-carbonil)-d-tirosil)-l-lisil)-4-(4-piridinil)-piperazina, procedimiento para su preparación y su uso como inhalado - Google Patents
Formulación en polvo que contiene el antagonista de cgrp 1-(n2-(3,5-dibromo-n-((4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-piperidinil)-carbonil)-d-tirosil)-l-lisil)-4-(4-piridinil)-piperazina, procedimiento para su preparación y su uso como inhaladoInfo
- Publication number
- UY28474A1 UY28474A1 UY28474A UY28474A UY28474A1 UY 28474 A1 UY28474 A1 UY 28474A1 UY 28474 A UY28474 A UY 28474A UY 28474 A UY28474 A UY 28474A UY 28474 A1 UY28474 A1 UY 28474A1
- Authority
- UY
- Uruguay
- Prior art keywords
- preparation
- oxoquinazolin
- dibromo
- procedure
- cgrp antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10338399A DE10338399A1 (de) | 2003-08-18 | 2003-08-18 | Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver |
Publications (1)
Publication Number | Publication Date |
---|---|
UY28474A1 true UY28474A1 (es) | 2005-03-31 |
Family
ID=34201779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY28474A UY28474A1 (es) | 2003-08-18 | 2004-08-17 | Formulación en polvo que contiene el antagonista de cgrp 1-(n2-(3,5-dibromo-n-((4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-piperidinil)-carbonil)-d-tirosil)-l-lisil)-4-(4-piridinil)-piperazina, procedimiento para su preparación y su uso como inhalado |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1658051A1 (de) |
JP (1) | JP2007502790A (de) |
CA (1) | CA2536048A1 (de) |
DE (1) | DE10338399A1 (de) |
UY (1) | UY28474A1 (de) |
WO (1) | WO2005018609A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10338402A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum |
DE10338407A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin |
EP3673895A1 (de) * | 2018-12-28 | 2020-07-01 | Université Libre de Bruxelles | Trockenpulverinhalationsformulierung und deren verwendung zur therapeutische behandlung von lungen |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1242211A (en) * | 1967-08-08 | 1971-08-11 | Fisons Pharmaceuticals Ltd | Pharmaceutical composition |
DE19937304C2 (de) * | 1999-08-10 | 2003-08-21 | Boehringer Ingelheim Pharma | Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen |
WO2001056581A1 (fr) * | 2000-02-04 | 2001-08-09 | Kissei Pharmaceutical Co., Ltd. | Preparation en poudre pour inhalation et inhalateur de poudre contenant cette preparation |
GB0014851D0 (en) * | 2000-06-16 | 2000-08-09 | Glaxo Group Ltd | Novel pharmaceutical formulation |
DE10139410A1 (de) * | 2001-08-17 | 2003-02-27 | Boehringer Ingelheim Pharma | Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne |
DE10206770A1 (de) * | 2002-02-19 | 2003-08-28 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096 |
DE10207026A1 (de) * | 2002-02-20 | 2003-08-28 | Boehringer Ingelheim Kg | Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung |
DE10338402A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum |
DE10338407A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin |
DE10338403A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum |
-
2003
- 2003-08-18 DE DE10338399A patent/DE10338399A1/de not_active Withdrawn
-
2004
- 2004-08-12 WO PCT/EP2004/009013 patent/WO2005018609A1/de active Application Filing
- 2004-08-12 CA CA002536048A patent/CA2536048A1/en not_active Abandoned
- 2004-08-12 EP EP04764017A patent/EP1658051A1/de not_active Withdrawn
- 2004-08-12 JP JP2006523577A patent/JP2007502790A/ja active Pending
- 2004-08-17 UY UY28474A patent/UY28474A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1658051A1 (de) | 2006-05-24 |
DE10338399A1 (de) | 2005-03-17 |
JP2007502790A (ja) | 2007-02-15 |
WO2005018609A1 (de) | 2005-03-03 |
CA2536048A1 (en) | 2005-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117571T1 (el) | Συνδυασμος αντιχολινεργικων και ανταγωνιστων υποδοχεα λευκοτριενιου για την αγωγη αναπνευστικων νοσηματων | |
ITMI20051999A1 (it) | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' | |
UA95199C2 (en) | Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | |
DK1267866T3 (da) | Behandling af respirationssygdomme | |
WO2005018603A3 (de) | Sprühgetrocknetes, amorphes bibn 4096, verfahren zu dessen herstellung sowie dessen verwendung als inhalativum | |
BRPI0508259A (pt) | derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo | |
GEP20084452B (en) | Sulfonamide derivatives for the treatment of diseases | |
MY179703A (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
MX355299B (es) | Inhibidores de cinasa de fosfoinositida 3 cristalina. | |
CR9832A (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
ECSP034559A (es) | Nuevos compuestos no-imidazol | |
TW200730178A (en) | Aerosol formulations for the inhalation of β-agonists | |
NO20090407L (no) | Aerosolformulering for inhalering av beta agonister | |
TW200745081A (en) | Compounds | |
CL2014000531A1 (es) | Composicion farmaceutica para inhalacion que comprende 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)ona; inhalador que proporciona una dosis nominal menor que 5 µg; y su uso en el tratamiento de una enfermedad pulmonar o pastologia asociada con actividad de los receptores ß2 adrenergicos. | |
EA201000677A1 (ru) | Сухие порошкообразные композиции, содержащие производные аскорбиновой кислоты | |
TW200640465A (en) | New pharmaceutically active compounds for the treatment of respiratory diseases | |
NO20052803L (no) | Komplekser av e-2-metoksy-n-(3-{4-(3-metyl-pyridin-3-yloksy)-fenylam ino)-kinazolin-6-yl}-allyl)acetamid, deres fremstillingsmate og bruk | |
WO2005011594A3 (en) | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease | |
UY28474A1 (es) | Formulación en polvo que contiene el antagonista de cgrp 1-(n2-(3,5-dibromo-n-((4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-piperidinil)-carbonil)-d-tirosil)-l-lisil)-4-(4-piridinil)-piperazina, procedimiento para su preparación y su uso como inhalado | |
UY30935A1 (es) | Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones. | |
UY27416A1 (es) | Uso de bibn4096 en combinación con otros fármacos antimigranosos para el tratamiento de migrana | |
AR045461A1 (es) | Formulacion en polvo que contiene el antagonista de cgrp 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1- piperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piridinil)-piperazina, procedimiento para su preparacion y su uso como inhalador | |
UY27674A1 (es) | Producto de inhalación en polvo que contiene el antagonista de cgrp, bibn4096, y procedimiento para su preparación. | |
DE60322110D1 (de) | Substituierte 4-(4-piperidin-yl-piperazin-1-yl)-azntagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150629 |